What Is GLP-3? The Triple Incretin Agonist Peptide Explained
“GLP-3” is not a newly discovered gut hormone—it’s a marketing nickname for next-generation weight-loss drugs that activate three different incretin receptors at once. Here’s what that means for real patients in 2026.
GLP-3 is an industry shorthand for investigational “triple incretin agonist” drugs—most notably retatrutide—that simultaneously stimulate the GLP-1, GIP, and glucagon receptors to curb appetite, boost metabolism, and improve blood sugar. It is not a natural human peptide, nor an FDA-approved medication in mid-2026. Early trials show roughly 25 % body-weight reduction over 48 weeks, but access is limited to clinical studies until regulators review safety and efficacy data.
- Participants in a Phase 2 obesity study lost up to 25 % of their starting weight after 48 weeks. [pubmed.ncbi.nlm.nih.gov]
- FDA submission is expected after full Phase 3 readouts finish in late 2026. [investor.lilly.com]
What GLP-3 Is—A Quick Definition
GLP-3 is the unofficial nickname for a class of triple incretin receptor agonists, led by the peptide retatrutide (LY3437943), that target the GLP-1, glucose-dependent insulinotropic peptide (GIP), and glucagon receptors in a single molecule. The “3” does not mean there is a newly discovered third glucagon-like peptide; it refers to three receptors activated. No product labeled GLP-3 is FDA-approved as of June 2026.
Why the confusion? Peptide-supplier websites started using the term “GLP-3” to signal the next generation after GLP-1 (single agonist) and dual agonists such as tirzepatide. The nickname stuck in social media, but regulators, major journals, and Eli Lilly all use the drug’s proper international non-proprietary name, retatrutide.
How GLP-3 Works in the Body
Triple agonists combine three complementary hormonal signals that tell your brain and liver to eat less and burn more. When retatrutide binds to the GLP-1 and GIP receptors, it slows gastric emptying, boosts insulin, and blunts appetite—just like semaglutide and tirzepatide. The added glucagon-receptor activation modestly raises resting energy expenditure, enhancing fat oxidation. [pubmed.ncbi.nlm.nih.gov]
Metabolic one-two-three punch: • GLP-1 arm—curbs hunger and lowers post-meal glucose • GIP arm—synergistic insulin boost, may protect muscle mass • Glucagon arm—nudges the liver to burn stored fat and increases calorie expenditure Together, these actions produced the largest average weight-loss ever recorded in an injectable obesity drug study. [pubmed.ncbi.nlm.nih.gov]
FDA Status and Clinical Trials
As of mid-2026 retatrutide is deep into Phase 3 trials but has not yet been filed for FDA review. Lilly reported positive topline data from the TRANSCEND-T2D-1 diabetes study in March 2026 and from the TRIUMPH-1 obesity study in May 2026, with additional readouts expected by December. [investor.lilly.com]
Key timeline highlights
| Milestone | Date | Result |
|---|---|---|
| Phase 2 obesity (NEJM) | June 2023 | 25 % mean weight loss at 48 weeks |
| Phase 2 diabetes (Lancet-Diabetes & Endocrinology) | July 2024 | 1.9 % A1C drop vs placebo at 36 weeks |
| TRANSCEND-T2D-1 Phase 3 topline | Mar 19 2026 | A1C –2.2 points; 17 % weight loss |
| TRIUMPH-1 Phase 3 topline | May 21 2026 | Up to 71 lb mean loss (≈24 %) |
| FDA filing projected | Q2 2027 | PDUFA decision likely 2028 |
Weight-Loss Results So Far
In the 338-person Phase 2 obesity trial, high-dose retatrutide cut body weight by an average 25 % over 48 weeks—about 60 pounds for a 240-lb participant. Nearly two-thirds of patients lost at least 20 % of initial weight, and one in four hit a 30 % landmark. [pubmed.ncbi.nlm.nih.gov]
| Drug (Weekly Dose) | Receptors Targeted | Avg Weight Loss | Trial Duration |
|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | GLP-1 only | 15 % | 68 wks (STEP-1) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/?term=33567185)) |
| Tirzepatide 15 mg (Mounjaro/Zepbound) | GLP-1 + GIP | 22 % | 72 wks (SURMOUNT-1) ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)) |
| Retatrutide 12 mg (“GLP-3”) | GLP-1 + GIP + Glucagon | 25 % | 48 wks (Phase 2) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37366315/)) |
See If GLP-1 Therapy Is Right for You Today
Talk with a licensed provider online in minutes—no waiting room.
Side Effects and Safety Signals
So far, GLP-3 side-effects look familiar to anyone who has used GLP-1 drugs—nausea (32 %), diarrhea (25 %), and vomiting (13 %)—but with a slightly higher rate of mild injection-site itch (18 %). Serious adverse events were rare (3 % vs 2 % with placebo) and mostly gallbladder-related. [pubmed.ncbi.nlm.nih.gov]
Expect the typical GI learning curve: • Start low, go slow: Doctors used a 4- to 8-week titration to cut nausea in half. • Stay hydrated: Diarrhea and vomiting drive most trial dropouts. • Watch heart rate: Mean resting pulse rose ~4 beats per minute—similar to semaglutide. These strategies mirror those in our first-time GLP-1 user guide.
Should you try a “research-grade” GLP-3 vial you saw online?
Check the column that fits your situation:
✅ Likely Safe to Wait for Prescription
- You can achieve ≥5 % weight loss with diet and an approved GLP-1 like Ozempic.
- No history of severe GI disease or pancreatitis.
- Comfortable waiting 18–24 months for FDA-reviewed safety data.
- Prefer medications dispensed by a U.S. pharmacy with insurance or discount card savings.
🏥 High-Risk—Talk to a Doctor
- Considering unregulated “research peptide” injections.
- BMI > 50 kg/m² with rapid weight-related complications.
- History of pancreatitis, gallstones, or medullary thyroid cancer.
- Taking insulin or multiple cardiometabolic drugs that raise hypoglycemia risk.
How GLP-3 Compares with Current GLP-1 and Dual Agonists
Triple agonists appear to deliver ~3–5 percentage-points greater weight loss than tirzepatide and ~10 points more than semaglutide, with broadly similar side-effect profiles. Whether that margin is worth waiting for depends on your personal goals, insurance coverage, and how well you tolerate existing drugs. See our complete GLP-1 weight-loss guide for details.
| Feature | Semaglutide | Tirzepatide | Retatrutide (GLP-3) |
|---|---|---|---|
| Dose Range | 0.25–2.4 mg | 2.5–15 mg | 1–12 mg* |
| Receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Avg Weight Loss | 15 % | 22 % | 25 % |
| FDA Approval | Yes (2021) | Yes (2023) | No (in Phase 3) |
| Weekly Pen Availability | Yes | Yes | Not yet |
*Highest dose tested in Phase 2; Phase 3 trials are exploring additional regimens.
Access, Cost, and Safe Next Steps
You can’t legally fill a GLP-3 prescription today, but you can position yourself for rapid access once the FDA gives a green light.
What to expect on price: Analysts predict launch pricing similar to Wegovy—about $1,330 per 28-day supply—but generic competition and Medicare price negotiations could shave 8–10 % by 2030. Use Rx.com to compare prices—most patients pay around $976 or less with a free discount card.
Action plan while you wait
- Meet weight-loss goals on existing medications; our 6-week Ozempic plan shows how to optimize early success.
- Keep insurance current; step-therapy blocks often waive once you prove response to GLP-1 therapy.
- Bookmark our true cost of GLP-1 medications article for real-time discounts.
- Avoid overseas or “research-only” peptide sellers—quality, dosing accuracy, and sterility are unverified.
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe abdominal pain — could signal pancreatitis.
- Persistent vomiting — risk of dehydration and electrolyte imbalance.
- Yellowing of skin or eyes — possible gallbladder or liver injury.
- Rapid heartbeat >120 bpm at rest — rare but reported tachycardia events. [pubmed.ncbi.nlm.nih.gov]
- Signs of allergic reaction — hives, swelling of face or throat.
- Severe constipation lasting >1 week — may require imaging to rule out obstruction.
- Thoughts of self-harm — mood changes have been seen, though infrequent.
Scientific References
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
- Rosenstock J et al. Retatrutide for People with Type 2 Diabetes: Randomised Phase 2 Trial. Lancet Diabetes Endocrinol. 2024.
- Eli Lilly & Co. Lilly’s Triple Agonist Retatrutide Demonstrated Significant Reductions in A1C and Weight in First Phase 3 Trial. Press Release, March 19 2026.
- Eli Lilly & Co. Retatrutide Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial. Press Release, May 21 2026.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021.
- SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
Frequently Asked Questions
Is GLP-3 the same as retatrutide?
Yes—when people say “GLP-3” they almost always mean retatrutide, the first triple incretin agonist in late-stage trials. The FDA and medical journals use the generic name retatrutide.
Can I get a GLP-3 prescription online right now?
No. Because retatrutide is still investigational, legitimate U.S. clinicians cannot prescribe it outside a registered clinical trial. Any website selling “GLP-3” vials for self-injection is marketing an unapproved research chemical.
Will GLP-3 cause more side effects than Ozempic?
Early data suggest gastrointestinal side-effects are similar to Ozempic, though mild injection-site itchiness is a bit more common. Serious adverse events remain low (<3 %) but longer Phase 3 follow-up is needed.
How much weight could I lose with GLP-3 compared with tirzepatide?
Phase 2 results show retatrutide producing about 3 percentage points more average weight loss than the highest tirzepatide dose. Individual responses vary, and head-to-head trials are still pending.
Is there an oral form of GLP-3 in development?
Not yet. Because triple agonists are larger peptide molecules, developers are focusing on once-weekly autoinjectors. Oral small-molecule GLP-1 agonists such as orforglipron are being explored separately.
Does GLP-3 build tolerance over time?
So far, weight loss curves with retatrutide continue downward for at least 48 weeks without a clear plateau. Whether tolerance or weight regain emerges beyond two years is still under study.
Could GLP-3 replace metabolic surgery?
If Phase 3 results mirror Phase 2, triple agonists may approach the average 25–30 % weight loss seen with sleeve gastrectomy. Long-term durability and remission of comorbidities will determine whether surgery remains necessary for some patients.
Take the First Step Toward Sustainable Weight Loss
Meet online with a U.S. provider who can prescribe today’s proven GLP-1 medications, monitor side-effects, and keep you informed about upcoming triple-agonist options.